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Abstract
Background: The type of pneumonia that is caused by the new coronavirus (SARS-CoV-2) has spread across the
world in a pandemic. It is not clear if COVID-19 patients have any lower urinary tract signs or symptoms.
Methods: The effect of COVID-19 on lower urinary tract function was studied in a prospective multi-centre,
observational study including 238 patients who were admitted with symptoms caused by COVID-19 to the
university hospital of Aachen in Germany and Tabriz in Iran.
Results: None of the patients reported to have any lower urinary tract symptoms. SARS-CoV-2 was found in the
urine of 19% of the tested patients.
The mortality rate in COVID-19 infected patients with microscopic haematuria together with white blood cells in
their urine, was significantly increased from 48 to 61% in the Tabriz cohort (p-value = 0.03) and from 30 to 35% in
the Aachen cohort (p-value =0.045). Furthermore, in the group of patients with SARS-CoV-2 urine PCR, the mortality
rate rose from 30 to 58%. (p-value =0.039).
Conclusion: Patients admitted with COVID-19 did not report to have any lower urinary tract symptoms, even those
patient who had a positive Urine SARS-CoV-2 PCR.
In addition, hematuria, WBC in urine as well as SARS- CoV-2 presence in urine, were found to be strong negative
prognostic factors in admitted COVID-19 patients.
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Background
The latest and most momentous threat to our world is
the pandemic caused by the new coronavirus (SARS-
CoV-2). Priorities in medical and surgical healthcare
have shifted drastically due to this pandemic. All fields
and specialties are facing new challenges and urology is
no exception.
The 2019 novel Coronavirus (2019-nCOV) was iso-
lated on the 7th of January by Chinese scientists who
then commenced genome sequencing which was later
provided to the World Health Organization (WHO) on
January 12th 2020 [1].
The WHO revealed the causative virus as Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) and the pneumonia as Coronavirus Disease 2019
(COVID-19). COVID-19 was declared a pandemic on
March 11th 2020 by the WHO [1].
Chest computed tomography (CT) and plain X-ray
play a crucial role in the detection of early pulmon-
ary changes and surveillance of patients with
COVID-19 [2, 3].
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Although respiratory symptoms are the predominant
presentation of COVID-19 among symptomatic infected
patients, it is important to emphasize that multiple
organ involvement including the gastrointestinal tract,
central nervous system, cardiovascular system, liver,
bone marrow and kidney have already been reported in
patients infected with SARS-CoV-2 [4, 5]. Besides severe
lung failure i.e. Acute Respiratory Distress Syndrome
(ARDS), heart and kidney failure have been recorded
among infected patients [6].
Hematuria associated with SARS-CoV-2 infection has
also been reported in both adults and children [5, 7].
A patient’s infectivity is determined by the presence of
the virus in different body fluids, secretions, and excreta.
The persistence and clearance of viral RNA from differ-
ent specimens of patients with 2019 novel coronavirus
disease (COVID-19) remained unclear. However, in both
human and animal studies, limited persistence of SARS-
COV-2 in urine has been detected [8, 9].
To date, there have been no studies published on the
effect of SARS- CoV-2 infection on the lower urinary
tract function.
In this study we aimed to investigate the effect of
SARS- CoV-2 infection on the lower urinary tract func-
tion in admitted COVID-19 patients.
Methods
Between February and June 2020, all patients who were
admitted to the two study hospitals (Aachen University
Hospital in Germany and Tabriz University Hospital in
Iran), and who tested positive for SARS-CoV-2 were in-
cluded in our study.
In this prospective multi-centre, observational study,
the blood and urine data where collected by the treating
medical staff and entered to the digital medical system.
For pathogen diagnosis (viral, bacterial, fungal), bron-
choscopy and broncho-alveolar lavage with a total vol-
ume of 160 ml was performed in all intubated patients.
In not intubated patients, real-time polymerase chain re-
action (PCR) was conducted from deep nasal and
pharyngeal swaps.
For SARS-CoV-2 detection the viral load was recorded
by PCR of respiratory material and in some cases in
urine. Threshold cycles for the S-gene < 20 were classi-
fied as high. Values > 30 were considered low viral load;
values between 20 and 30 were classified as moderate
viral load.
Serum, urine, and stool were also tested for SARS-
CoV-2. Urine parameters were recorded over time, such
as erythrocyte count (RBC), white blood cell count
(WBC) and proteinuria. Descriptive and analytical statis-
tics including chi-square test and Fisher’s Exact test was
employed using IBM SPSS (version 24). All analyses
were considered significant when p < 0.05.
Results
The study population was made up of two cohorts of
COVID-19 patients who were hospitalized in the Uni-
versity Hospitals Aachen in Germany and Tabriz in Iran.
A total of 238 patients were included in our study. The
two cohorts existed of: 133 patients (41 females - 92
males) who were admitted at the University Hospital in
Aachen, Germany and 105 patients (39 females and 66
males) who were admitted at the University Hospital of
Tabriz in Iran. The patients’ data and characteristics are
listed in Table 1.
The average age of all patients studied was 65 years. In
the Tabriz-cohort, the average age was 60 years (range
16–89) and in the Aachen-cohort it was 65 years (25–
88).
The main primary symptoms that were reported were:
fever, shortage of breath and coughing. None of the
studied patients reported to have any lower urinary tract
symptoms.
The average time between the occurrence of symp-
toms and hospitalization in both cohorts was four days.
From all admitted patients, 90 patients passed away:
40 in Aachen (27 male, 13 female) and 50 in Tabriz (36
male, 14 female).
From the included 238 COVID-19 infected patients,
181 patients had a urinalysis of whom, 131 patients had
microscopic hematuria (72%) and 99 patients had white
blood cells in their urine (54%), (Table 1).
The mortality rate in COVID-19 infected patients
with microscopic hematuria together with white blood
cells in their urine, was significantly increased from
48 to 61% in the Tabriz cohort (p-value = 0.03) and
from 30 to 35% in the Aachen cohort (p-value =
0.045), as shown in Table 2. In addition, the urine of
63 patients admitted in Aachen, was checked for
SARS-CoV-2 presence by PCR. From these patients,
51 were negative (81%) of whom 13 patients died
(25,5%). Moreover, 12 patients tested positive for
SARS-CoV-2 in their urine (19%). From these 12 pa-
tients, 7 patients died (58%). This means that, in the
group of patients with SARS-CoV-2 urine PCR, the
mortality rate rose from 30 to 58%. (p-value =0.039)
(Table 2).
From the total of 238 patients included in our study,
122 patients had a bacterial urine culture of whom 50
patients (41%) had a positive bacterial urine culture. The
most common uropathogens were (E. coli, Klebsiella
pneumoniae and Proteus). The mortality among the pa-
tients with a positive bacterial urine culture was 26% (13
patients).
Discussion
The diagnosis of COVID-19 can be challenging as pa-
tients often present with unclear or even subclinical
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signs of disease [10]. In our study, none of the COVID-
19 patients reported any LUTS or had urinary retention
or incontinence. Even in those 12 patients who tested
positive for viral RNA in their urine. A study that fo-
cused on an increase in urinary frequency as a symptom
of COVID-19 identified this in seven males out of 57 pa-
tient admitted with COVID-19 [7]. Interestingly, no viral
RNA was found in the urine of these patients [7].
Regarding the urine analysis of COVID-19 patients
in our study, we can state that the presence of WBC
and RBC in the urine as well as the presence of
COVID-19 virus in urine, seems directly related to
an increase of mortality in these patients (Table 2).
In patients with microscopic hematuria together with
white blood cells in their urine, the mortality was
significantly increased from 48 to 61% in the Tabriz
cohort (p-value = 0.03) and from 30 to 35% in the
Aachen cohort (p-value =0.045). In addition,
Moreover, in the group of patients with SARS-CoV-
2 urine PCR, the mortality rate rose from 30 to 58%.
(p-value =0.039).
In our series, the two cohorts of Tabriz and Aachen,
were not statistically different regarding age and male-
female ratio (p-value 0,18 and 0,28).
The mortality rate in Tabriz (48%) was significantly
higher than in Aachen 30% (p-value 0.005). This might
be explained by many factors that were not investigated
in our study such as the availability of resources as well
as patient comorbidities.
There were significantly less patients who had a urine
culture in the Tabriz cohort which would explain the
differences in the positive culture rates.
Microscopic haematuria was seen in a majority of
tested COVID-19 patients of Tabriz and Aachen (68 and
78%, respectively) and was not due to a positive bacterial
urine culture in most cases (Table 1).







Age in years (Range) 60 (16–89) 65 (25–88) 0.18
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Female 39 (37%) 41 (30%) 0.28
Male 66 (63%) 92 (70%)
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12 positive (19%)
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(14 women, 36 men)
40 (30%)
(13 women, 27 men)
0.005
aN. is the total number of the included COVID-19 patients who had an analysis of each mentioned parameter
Table 2 Comparison of mortality according to different urine findings of COVID-19 Patients

































Positive Urine COVID PCR test – N = 63
12 (19%)
– N = 12
7 (58%)
RBC Red blood cell count, WBC White blood cell count
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Hematuria has been reported in other viral respiratory in-
fections including influenza A and B as well as adenovirus
[11]. Moreover, kidney injury in hospitalized patients with
COVID-19 appears to be a frequent finding [12]. Different
symptoms have been reported ranging from, from mild
hematuria to severe renal failure [11]. The underlaying
pathophysiology is not well known. However, hypotheses
have been put forward on the cytopathic effects of the virus
as well as the immune-complexes mediated damage [11].
Furthermore, indirect effects on renal tissue, including hyp-
oxia, and rhabdomyolysis due to the cytokine inflammatory
response to the virus might play a role as well.
In our study, we have found increase white blood cells
(WBC) in the urine of about half of the tested COVID-
19 patients (Table 2). In most of the cases there was a
negative bacterial urine culture.
The time from suspected exposure to the onset of
COVID-19 and worsening hematuria ranged between 5
and 8 days in the reported cases.
In the face of a possible increase and new waves of the
pandemic, clinicians should be aware that a non-typical
course of hematuria or increased WBC in urine might be
related to a SARS- CoV-2 infection, especially in patients
with a preexisting condition of the urinary tract [12].
It is known that the mortality rates are high between the
COVID-19 patients with acute kidney injury (60–90%) [13].
Viral RNA has been identified in the urine samples of
COVID-19 patients even after recovery from respiratory
symptoms [8]. In our study, SARS-CoV-2 was found in
the urine of 19% of the tested patients.
Angiotensin-converting enzyme 2 (ACE2), the recep-
tor for SARS-CoV-2 and responsible for host cell entry
might be a another possible link to multi organ failure of
the COVID-19 patients. ACE2 is expressed different or-
gans such as the hearth, the gastrointestinal tract, bone
marrow and kidneys and bladder [14].
Recent studies revealed the cell-surface protein
angiotensin-converting enzyme 2 (ACE2) as the main re-
ceptor for the SARS-CoV-2 spike protein [15]. Investiga-
tions of the distribution across many different tissues
revealed that ACE2 expression was highest in lung, in-
testines, and kidney, but it was also high in 2.4% of
urothelial cells, which might be a link with lower urinary
tract symptoms [16]. In Next to the kidney tissue blad-
der urothelium has cells that express ACE2 [12, 16, 17].
We hypothesize a possible link between the lower urin-
ary system and SARS-CoV-2 through the ACE2 (Fig. 1).
Our study is limited by the relatively small sample size
and the emergency setting in which most patients were
included in the study. More future studies with larger
sample size are needed to determine the exact effect of
SARS- CoV-2 infections on the lower urinary tract.
Conclusion
We found no lower urinary tract symptoms in patients
admitted with COVID-19.
Fig. 1 A cartoon of SARS-CoV-2 Infection in the Urinary Bladder produced by the authors
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Even the presence of SARS- CoV-2 did not cause any
urinary symptoms. It can be concluded that hematuria,
WBC in urine as well as SARS- CoV-2 positivity in urine
are negative prognostic factors in admitted COVID-19
patients.
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